Segments - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Segment Reporting Information [Line Items]
Total segment expense	$ 27,548	$ 23,407	$ 32,565
Net loss	$ 62,293	27,029	41,307
Number of operating segments	1
Operating Segment
Segment Reporting Information [Line Items]
Compensation and benefits, excluding stock-based compensation	$ 7,438	6,737	7,239
Stock-based compensation	3,003	2,148	2,691
Drug manufacturing	2,485	2,195	11,213
Clinical trial	4,148	2,716	3,159
Outside general and administrative	3,101	2,703	2,978
Facilities and insurance	3,219	3,160	3,342
Other segment items (1)	4,154	3,748	1,943
Total segment expense	27,548	23,407	32,565
Non-operating income and expense, net	34,745	3,622	8,742
Net loss	$ (62,293)	$ (27,029)	$ (41,307)
Number of operating segments	1